CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 72 enrolled
Drug / intervention
ACUVUE OASYS® 1-Day for Astigmatism - TAM 24 +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04794270
NCT04794270N/ACompleted
CompareCT.gov

Evaluation of ACUVUE OASYS® 1-Day for Astigmatism Lenses Produced on a New Manufacturing Line

Johnson & Johnson Vision Care, Inc.·interventional·Posted Mar 12, 2021·Updated May 18, 2022

In Brief

A clinical study evaluating ACUVUE OASYS® 1-Day for Astigmatism - TAM 24 and ACUVUE OASYS® 1-Day for Astigmatism for Visual Acuity. Completed, enrolled 72 participants across 5 sites.

Detailed Summary

This is a bilateral, dispensing, randomized, controlled, double-masked, 2×2 cross-over study to evaluate the clinical performance of ACUVUE OASYS® 1-Day for Astigmatism contact lenses produced on a recently qualified manufacturing line.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVisual Acuity
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedMar 12, 2021
Enrollment StartMar 2, 2021
Primary CompletionApr 13, 2021
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 5.3 years ago

Interventions

ACUVUE OASYS® 1-Day for Astigmatism - TAM 24device

TEST

ACUVUE OASYS® 1-Day for Astigmatismdevice

CONTROL